Biotech news
Americas
The US District Court for the District of Massachusetts has issued a ruling on a summary judgment motion filed by Celltrion Healthcare and Hospira, invalidating a Janssen patent related to Remicade. 18 August 2016
Americas
The US Supreme Court’s Mayo and Myriad decisions have brought challenges to subject matter eligibility to the forefront in the biomedical industry, but they do not signal the end of biomedical patents. Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report. 18 August 2016
Americas
The US Patent and Trademark Office has rejected the Broad Institute of MIT and Harvard’s request for a time extension before the start of its patent dispute surrounding the CRISPR technology. 16 August 2016
Asia-Pacific
In Australia, laws governing the patentability of inventions directed to gene-based technology, including isolated naturally occurring and artificial gene sequences, are contentious. Unlike the US situation, the law on patentability of inventions involving “principles of nature” in Australia has yet to be considered judicially, but that is about to change, says Grant Shoebridge of Shelston IP. 16 August 2016
Asia
Even if India moves towards a patent-unfriendly environment for green technologies, the pro-patent and pro-environment lobbies can coexist and meet their respective goals, argue Swarup Kumar and Jitesh Kumar of Remfry & Sagar. 11 August 2016
Americas
Amgen has entered into a global agreement with Advaxis, allowing for the development and commercialisation of ADXS-NEO, a preclinical cancer immunotherapy treatment. 10 August 2016
Americas
The US and China take very different approaches to the patentability of a range of inventions in the life sciences field, as Yu Guo of China Patent Agent reports. 9 August 2016
Asia-Pacific
A new fund dedicated to accelerate the development and commercialisation of Australian biomedical discoveries has officially launched. 5 August 2016
Americas
Fustibal, a targeted therapeutics biotechnology start-up, has filed an inter partes review petition challenging a patent owned by German pharmaceutical company Bayer. 4 August 2016
Americas
Editas Medicine, a US genome-editing company, announced yesterday that it has entered into an exclusive licensing agreement with Massachusetts General Hospital to access CRISPR technology. 4 August 2016